Tempus AI (TEM) said Wednesday it entered a multi-year collaboration with Genialis to advance the development and validation of RNA-based biomarker algorithms for cancer treatment.
Financial details weren't disclosed.
Genialis will leverage Tempus' multimodal dataset to validate its AI foundation model, which is based on data from around 1 million RNA-sequencing samples.
Through this partnership, Genialis can now use Tempus' multimodal dataset and analytics platform, Lens, to access de-identified patient records and tools for signature validation, aiding in the market launch of its clinical algorithms.
Tempus, in turn, gains the right to evaluate and potentially license these algorithms for use in its xR platform, the company said.
Shares of Tempus were down 2.1% in recent trading.
Price: 38.06, Change: -0.81, Percent Change: -2.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.